To figure out if the effect of FRG1 expression on prostate cancer cells is irrespective of androgen receptor status, we used LNCaP cell lines with ectopic expression of FRG1 and depletion of FRG1 along with their controls (Fig. 4a), for cell based assays. The gene discussed is AR; the disease is prostate cancer.